Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG)

doi:10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Task Force Members
, ESC National Cardiac Societies
, ESC Committee for Practice Guidelines (CPG)

Cardiology Department
University of Geneva
University of Oxford
Department of Pharmacological and Biomolecular Sciences
University of Milan
Cardiology
University of Bern
Epidemiology and Preventive Pharmacology Service (SEFAP)
IRCCS Multimedica - Milano
Hospital de La Santa Creu I Sant Pau
Sorbonne Université
Division of Endocrinology- Metabolism
Cardiology
Trinity College Dublin
Public Health and Primary Care
Ghent University
Cardiology
Leiden University
University of Cambridge
Department of Cardiology
Charité – Universitätsmedizin Berlin
Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin
German Centre for Cardiovascular Research
Queen Mary University of London
Preventive Cardiology
University of Oslo
Department of Clinical Medicine and Surgery
University of Naples Federico II
Cardiac Department
TIMI Study Group
Brigham and Women’s Hospital
Research Program for Clinical and Molecular Metabolism
University of Helsinki
Cardiology
Hacettepe University
Institute of Medicine
University of Gothenburg
Algerian Society of Cardiology
Armenian Cardiologists Association
Austrian Society of Cardiology
Azerbaijan Society of Cardiology
Belgian Society of Cardiology
Association of Cardiologists of Bosnia and Herzegovina
Bulgarian Society of Cardiology
Cyprus Society of Cardiology
Czech Society of Cardiology
Danish Society of Cardiology
Egyptian Society of Cardiology
Estonian Society of Cardiology
Finnish Cardiac Society
French Society of Cardiology
Georgian Society of Cardiology
German Cardiac Society
Hellenic Society of Cardiology
Hungarian Society of Cardiology
Icelandic Society of Cardiology
Irish Cardiac Society
Israel Heart Society
Italian Federation of Cardiology
Association of Cardiologists of Kazakhstan
Kosovo Society of Cardiology
Kyrgyz Society of Cardiology
Latvian Society of Cardiology
Lebanese Society of Cardiology
Lithuanian Society of Cardiology
Luxembourg Society of Cardiology

Zinātniskās darbības rezultāts: Devums žurnālam › Komentārs/diskusija/piezīme

11 Atsauces (Scopus)

Kopsavilkums

In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

Oriģinālvaloda	Angļu
Lapas (no-līdz)	80-82
Lapu skaits	3
Žurnāls	Atherosclerosis
Sējums	294
DOIs	https://doi.org/10.1016/j.atherosclerosis.2019.12.004
Publikācijas statuss	Publicēts - febr. 2020
Ārēji publicēts	Jā

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

3. IAM — Laba Veselība un Labbūtība

Piekļuve Dokumentiem

10.1016/j.atherosclerosis.2019.12.004

Citi faili un saites

Saite uz publikāciju Scopus

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))”. Kopā tie veido unikālu nospiedumu.

Citēt šo

Task Force Members, ESC National Cardiac Societies, & ESC Committee for Practice Guidelines (CPG) (2020). Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). Atherosclerosis, 294, 80-82. https://doi.org/10.1016/j.atherosclerosis.2019.12.004

Task Force Members ; ESC National Cardiac Societies ; ESC Committee for Practice Guidelines (CPG). / Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). (gadā): Atherosclerosis. 2020 ; Sēj. 294. lpp. 80-82.

@article{3cb11c16c8ec4730bb2377d995807459,

title = "Corrigendum to {\textquotedblleft}2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk{\textquotedblright} (Atherosclerosis (2019) 290 (140{\textendash}205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))",

abstract = "In row 4 of Table 3, {\textquoteleft}should{\textquoteright} should read as {\textquoteleft}may{\textquoteright}; In 4.2.1, paragraph 3, {\textquoteleft}should{\textquoteright} should read {\textquoteleft}may{\textquoteright} to read {\textquoteleft}Overall, CAC score assessment with CT may be considered in individuals … {\textquoteright} Also in the second row of {\textquoteleft}Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,{\textquoteright} the Class should read {\textquoteleft}llb{\textquoteright}; In the second paragraph of 7.5.2, {\textquoteleft}5{\textendash}10 mg of monacolin K{\textquoteright} should read {\textquoteleft}2.5{\textendash}10 mg{\textquoteright}; and in the Key messages section, number 4, {\textquoteleft}ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read {\textquoteleft}ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.",

author = "\{Task Force Members\} and \{ESC National Cardiac Societies\} and \{ESC Committee for Practice Guidelines (CPG)\} and Francois Mach and Colin Baigent and Catapano, \{Alberico L.\} and Koskinas, \{Konstantinos C.\} and Manuela Casula and Lina Badimon and Chapman, \{M. John\} and \{De Backer\}, \{Guy G.\} and Victoria Delgado and Ference, \{Brian A.\} and Graham, \{Ian M.\} and Alison Halliday and Ulf Landmesser and Borislava Mihaylova and Pedersen, \{Terje R.\} and Gabriele Riccardi and Richter, \{Dimitrios J.\} and Sabatine, \{Marc S.\} and Taskinen, \{Marja Riitta\} and Lale Tokgozoglu and Olov Wiklund and Djamaleddine Nibouche and Zelveian, \{Parounak H.\} and Peter Siostrzonek and Ruslan Najafov and \{van de Borne\}, Philippe and Belma Pojskic and Arman Postadzhiyan and Lambros Kypris and Jind{\v r}ich {\v S}pinar and Larsen, \{Mogens Lytken\} and Eldin, \{Hesham Salah\} and Margus Viigimaa and Strandberg, \{Timo E.\} and Jean Ferrieres and Rusudan Agladze and Ulrich Laufs and Loukianos Rallidis and Laszlo Bajnok and Thorbjorn Gudjonsson and Vincent Maher and Yaakov Henkin and Gulizia, \{Michele Massimo\} and Aisulu Mussagaliyeva and Gani Bajraktari and Alina Kerimkulova and Gustavs Latkovskis and Omar Hamoui and Rimvydas Slapikas and Laurent Visser",

note = "Publisher Copyright: {\textcopyright} 2019 [The Author/The Authors]",

year = "2020",

month = feb,

doi = "10.1016/j.atherosclerosis.2019.12.004",

language = "English",

volume = "294",

pages = "80--82",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

}

Task Force Members, ESC National Cardiac Societies & ESC Committee for Practice Guidelines (CPG) 2020, 'Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))', Atherosclerosis, sēj. 294, lpp. 80-82. https://doi.org/10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). / Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG).
(gadā): Atherosclerosis, Sēj. 294, 02.2020, lpp. 80-82.

Zinātniskās darbības rezultāts: Devums žurnālam › Komentārs/diskusija/piezīme

TY - JOUR

T1 - Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias

T2 - lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

AU - Task Force Members

AU - ESC National Cardiac Societies

AU - ESC Committee for Practice Guidelines (CPG)

AU - Mach, Francois

AU - Baigent, Colin

AU - Catapano, Alberico L.

AU - Koskinas, Konstantinos C.

AU - Casula, Manuela

AU - Badimon, Lina

AU - Chapman, M. John

AU - De Backer, Guy G.

AU - Delgado, Victoria

AU - Ference, Brian A.

AU - Graham, Ian M.

AU - Halliday, Alison

AU - Landmesser, Ulf

AU - Mihaylova, Borislava

AU - Pedersen, Terje R.

AU - Riccardi, Gabriele

AU - Richter, Dimitrios J.

AU - Sabatine, Marc S.

AU - Taskinen, Marja Riitta

AU - Tokgozoglu, Lale

AU - Wiklund, Olov

AU - Nibouche, Djamaleddine

AU - Zelveian, Parounak H.

AU - Siostrzonek, Peter

AU - Najafov, Ruslan

AU - van de Borne, Philippe

AU - Pojskic, Belma

AU - Postadzhiyan, Arman

AU - Kypris, Lambros

AU - Špinar, Jindřich

AU - Larsen, Mogens Lytken

AU - Eldin, Hesham Salah

AU - Viigimaa, Margus

AU - Strandberg, Timo E.

AU - Ferrieres, Jean

AU - Agladze, Rusudan

AU - Laufs, Ulrich

AU - Rallidis, Loukianos

AU - Bajnok, Laszlo

AU - Gudjonsson, Thorbjorn

AU - Maher, Vincent

AU - Henkin, Yaakov

AU - Gulizia, Michele Massimo

AU - Mussagaliyeva, Aisulu

AU - Bajraktari, Gani

AU - Kerimkulova, Alina

AU - Latkovskis, Gustavs

AU - Hamoui, Omar

AU - Slapikas, Rimvydas

AU - Visser, Laurent

PY - 2020/2

Y1 - 2020/2

N2 - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

AB - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

UR - https://www.scopus.com/pages/publications/85076858833

U2 - 10.1016/j.atherosclerosis.2019.12.004

DO - 10.1016/j.atherosclerosis.2019.12.004

M3 - Comment/debate/note

C2 - 31870624

AN - SCOPUS:85076858833

SN - 0021-9150

VL - 294

SP - 80

EP - 82

JO - Atherosclerosis

JF - Atherosclerosis

ER -

Task Force Members, ESC National Cardiac Societies, ESC Committee for Practice Guidelines (CPG). Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). Atherosclerosis. 2020 febr.;294:80-82. doi: 10.1016/j.atherosclerosis.2019.12.004